Kesheng Wang1,2, Xue Chen3, Stephen C Ward4, Ying Liu1,2, Youssoufou Ouedraogo1, Chun Xu5, Arthur I Cederbaum6, Yongke Lu7,8. 1. Department of Biostatistics and Epidemiology, College of Public Health, East Tennessee State University, Johnson City, TN, USA. 2. Center of Excellence for Inflammation, Infectious Disease and Immunity, East Tennessee State University, Johnson City, TN, USA. 3. Department of Health Sciences, College of Public Health, East Tennessee State University, Johnson City, TN, USA. 4. Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA. 5. Department of Health and Biomedical Sciences, College of Health Affairs, University of Texas Rio Grande Valley, Brownsville, TX, 78520, USA. 6. Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA. 7. Department of Health Sciences, College of Public Health, East Tennessee State University, Johnson City, TN, USA. luy004@etsu.edu. 8. Center of Excellence for Inflammation, Infectious Disease and Immunity, East Tennessee State University, Johnson City, TN, USA. luy004@etsu.edu.
Abstract
BACKGROUND/ OBJECTIVES: CYP2A6 (CYP2A5 in mice) is mainly expressed in the liver. Hepatic CYP2A6 expression is increased in patients with non-alcoholic fatty liver disease (NAFLD). In mice, hepatic CYP2A5 is induced by high fat diet (HFD) feeding. Hepatic CYP2A5 is also increased in monosodium glutamate-induced obese mice. NAFLD is associated with obesity. In this study, we examined whether obesity is related to CYP2A6. SUBJECTS/ METHODS: Obesity genetic association study: The SAGE is a comprehensive genome-wide association study (GWAS) with case subjects having a lifetime history of alcohol dependence and control subjects never addicted to alcohol. We used 1030 control individuals with self-reported height and weight. A total of 12 single nucleotide polymorphisms (SNP) within the CYP2A6 gene were available. Obesity was determined as a BMI ≥30: 30-34.9 (Class I obesity) and ≥35 (Class II and III obesity). Animal experiment study: CYP2A5 knockout (cyp2a5-/-) mice and wild type (cyp2a5+/+) mice were fed HFD for 14 weeks. Body weight was measured weekly. After an overnight fast, the mice were sacrificed. Liver and blood were collected for biochemical assays. RESULTS: Single marker analysis showed that three SNPs (rs8192729, rs7256108, and rs7255443) were associated with class I obesity (p < 0.05). The most significant SNP for obesity was rs8192729 (odds ratio (OR) = 1.94, 95% confidence intervals = 1.21-3.10, p = 0.00582). After HFD feeding, body weight was increased in cyp2a5-/- mice to a greater extent than in cyp2a5+/+ mice, and fatty liver was more pronounced in cyp2a5-/- mice than in cyp2a5+/+ mice. PPARα deficiency in cyp2a5-/- mice developed more severe fatty liver, but body weight was not increased significantly. CONCLUSION: CYP2A6 is associated with human obesity; CYP2A5 protects against obesity and NAFLD in mice. PPARα contributes to the CYP2A5 protective effects on fatty liver but it opposes to the protective effects on obesity.
BACKGROUND/ OBJECTIVES:CYP2A6 (CYP2A5 in mice) is mainly expressed in the liver. Hepatic CYP2A6 expression is increased in patients with non-alcoholic fatty liver disease (NAFLD). In mice, hepatic CYP2A5 is induced by high fat diet (HFD) feeding. Hepatic CYP2A5 is also increased in monosodium glutamate-induced obesemice. NAFLD is associated with obesity. In this study, we examined whether obesity is related to CYP2A6. SUBJECTS/ METHODS:Obesity genetic association study: The SAGE is a comprehensive genome-wide association study (GWAS) with case subjects having a lifetime history of alcohol dependence and control subjects never addicted to alcohol. We used 1030 control individuals with self-reported height and weight. A total of 12 single nucleotide polymorphisms (SNP) within the CYP2A6 gene were available. Obesity was determined as a BMI ≥30: 30-34.9 (Class I obesity) and ≥35 (Class II and III obesity). Animal experiment study: CYP2A5 knockout (cyp2a5-/-) mice and wild type (cyp2a5+/+) mice were fed HFD for 14 weeks. Body weight was measured weekly. After an overnight fast, the mice were sacrificed. Liver and blood were collected for biochemical assays. RESULTS: Single marker analysis showed that three SNPs (rs8192729, rs7256108, and rs7255443) were associated with class I obesity (p < 0.05). The most significant SNP for obesity was rs8192729 (odds ratio (OR) = 1.94, 95% confidence intervals = 1.21-3.10, p = 0.00582). After HFD feeding, body weight was increased in cyp2a5-/- mice to a greater extent than in cyp2a5+/+ mice, and fatty liver was more pronounced in cyp2a5-/- mice than in cyp2a5+/+ mice. PPARα deficiency in cyp2a5-/- mice developed more severe fatty liver, but body weight was not increased significantly. CONCLUSION:CYP2A6 is associated with humanobesity; CYP2A5 protects against obesity and NAFLD in mice. PPARα contributes to the CYP2A5 protective effects on fatty liver but it opposes to the protective effects on obesity.
Authors: Michael K Badman; Pavlos Pissios; Adam R Kennedy; George Koukos; Jeffrey S Flier; Eleftheria Maratos-Flier Journal: Cell Metab Date: 2007-06 Impact factor: 27.287
Authors: Xue Chen; George K Acquaah-Mensah; Krista L Denning; Jonathan M Peterson; Kesheng Wang; James Denvir; Feng Hong; Arthur I Cederbaum; Yongke Lu Journal: Am J Physiol Gastrointest Liver Physiol Date: 2020-09-02 Impact factor: 4.052
Authors: Ximena M Bustamante-Marin; Jenna L Merlino; Emily Devericks; Meredith S Carson; Stephen D Hursting; Delisha A Stewart Journal: Front Endocrinol (Lausanne) Date: 2021-03-17 Impact factor: 6.055
Authors: Stanislav Listopad; Christophe Magnan; Aliya Asghar; Andrew Stolz; John A Tayek; Zhang-Xu Liu; Timothy R Morgan; Trina M Norden-Krichmar Journal: JHEP Rep Date: 2022-08-18
Authors: Shannon Doherty Lyons; Jason L Blum; Carol Hoffman-Budde; Pamela B Tijerina; M Isabel Fiel; Daniel J Conklin; Francesca Gany; Joseph A Odin; Judith T Zelikoff Journal: Int J Environ Res Public Health Date: 2020-10-28 Impact factor: 4.614